Business
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline c
About this update from Volitionrx Limited
[{"type":"text","content":"The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.","length":614,"tagName":"p"},{"type":"image","alt":"Elevated plasma nucleosome concentrations in feline LSA","displaySize":"","headline":null,"caption":"Elevated plasma nucleosome concentrations in feline LSA","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/713498ecc0db73aaa95383bcfa58fc17"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Afi22Qom_7wE61r6aCMUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5Nw--/https://media.zenfs.com/en/prnewswire.com/713498ecc0db73aaa95383bcfa58fc17","width":400,"height":225},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LB4tAiimkDAZHK142HhZ4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/prnewswire.com/713498ecc0db73aaa95383bcfa58fc17","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr Annalisa Canale, Volition and first author on the paper commented:","length":69,"tagName":"p"},{"type":"text","content":""Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early.","length":117,"tagName":"p"},{"type":"text","content":""Building on our prior findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats.","length":212,"tagName":"p"},{"type":"text","content":""Nucleosome levels ...